AstraZeneca could leave the London Stock Exchange over dissatisfaction with regulations, which would significantly affect the FTSE 100 index.

British pharmaceutical company AstraZeneca, with a market capitalization of £161.2 billion, is considering a move to the US stock exchange because of dissatisfaction with UK regulations. The decision could reflect a wider trend in which companies prefer US markets for higher valuations and a bigger investor base. Experts believe AstraZeneca's departure would be a significant loss for the London Stock Exchange, which risks losing its status as a global financial center.